Zynerba Pharmaceuticals Inc (ZYNE.OQ)
ZYNE.OQ on NASDAQ Stock Exchange Global Market
6.27USD
22 Oct 2018
6.27USD
22 Oct 2018
Change (% chg)
$-0.52 (-7.66%)
$-0.52 (-7.66%)
Prev Close
$6.79
$6.79
Open
$6.76
$6.76
Day's High
$6.79
$6.79
Day's Low
$6.12
$6.12
Volume
106,119
106,119
Avg. Vol
130,833
130,833
52-wk High
$15.12
$15.12
52-wk Low
$5.59
$5.59
About
Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which... (more)
Overall
| Beta: | -- |
| Market Cap(Mil.): | $128.07 |
| Shares Outstanding(Mil.): | 13.26 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| ZYNE.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 85.41 | 33.64 |
| EPS (TTM): | -2.62 | -- | -- |
| ROI: | -55.80 | 0.21 | 14.27 |
| ROE: | -55.80 | 1.17 | 15.99 |
BRIEF-Zynerba Pharmaceuticals Reports Q1 Loss Of $0.91 Per Share
* ZYNERBA PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS
BRIEF-Zynerba Pharmaceuticals Says ZYN002 Was Shown To Be Well Tolerated Through 12 Months Of Treatment In Star 2 Study
* ZYNERBA PHARMACEUTICALS SAYS ZYN002 WAS SHOWN TO BE WELL TOLERATED THROUGH 12 MONTHS OF TREATMENT IN STAR 2
Estimates